Peregrine Pharma (PPHM) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Roth Remains Neutral on Peregrine Pharma (PPHM); Pipeline Advancing Well, but Catalysts Remain
September 9, 2016 11:09 AM EDTRoth Capital affirms Peregrine Pharma (Nasdaq: PPHM) with a Neutral rating and $0.50 price target following Q1 results issued Thursday night.
Analyst Joseph Pantginis noted Peregrine's efforts to advances its pipeline. The analyst commented: In our opinion, PPHM is making strategic decisions in order to grow and become profitable through a two pronged approach:... More
